An international meta-analysis has highlighted tirzepatide, a dual GIP and GLP-1 receptor agonist, as an effective agent for weight management in both diabetic and non-diabetic patients. The systematic review underscores tirzepatide's safety and efficacy profiles, confirming its expanding role in metabolic disease treatment and weight reduction strategies. These findings support broader clinical applications of this novel therapeutic class.